| 发明名称 |
4-pregenen-11β-17-21-triol-3,20-dione derivatives |
| 摘要 |
The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation. |
| 申请公布号 |
US9433631(B2) |
申请公布日期 |
2016.09.06 |
| 申请号 |
US201414533847 |
申请日期 |
2014.11.05 |
| 申请人 |
Allergan, Inc. |
发明人 |
Edelman Jeffrey L.;Nehme Alissar;Malone Thomas C. |
| 分类号 |
A61K31/58;A61K31/573;C07J7/00;C07J17/00;C07J31/00;A61K31/56;A61K9/00;C07J5/00;A61K31/575 |
主分类号 |
A61K31/58 |
| 代理机构 |
|
代理人 |
Bass Jonathan |
| 主权项 |
1. A method of treating a disorder associated with glucocorticoid receptor modulation, which comprises administering to a patient an ophthalmically acceptable pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: |
| 地址 |
Irvine CA US |
